Pages

Showing posts with label mammary carcinoma. Show all posts
Showing posts with label mammary carcinoma. Show all posts

Thursday, November 15, 2012

Developing new therapies for feline mammary cancer

Figueira AC, Teodosio AS, Carvalheira J, Lacerda M, de Matos A and Gartner F. P-cadherin expression in feline mammary tissues. Veterinary Medicine International. 2012; 2012. [Free, full text article}

Feline mammary gland tumors are the third most common neoplasia in the domestic cat after skin and lymphohematopoietic tumors, accounting for 17% of all neoplasms in female cats (but rare in male cats). Mammary epithelial tumors are the most common type of feline mammary tumor, with adenocarcinomas (i.e., tubular, papillary, or solid) predominating. Tumors occur at a mean age between 10 to 12 years with Siamese, domestic short-haired, and tri-colored cats having an increased risk. Unfortunately, most cats have advanced disease when first presented to veterinarians, averaging 5 months after the neoplasia is first noticed. Treatment of choice is radical mastectomy of all glands on the affected side or bilateral mastectomy if possible, because of the high local recurrence rate, high rate of metastasis, and the frequent multicentric origin of feline mammary gland tumors. Often surgery for the opposite side is staged 2-4 weeks later. Also, all regional lymph nodes should be palpated and removed if enlarged. Ovariohysterectomy at an early age (< 6 months old) has a significant sparing effect. Significant factors affecting survival include the size, extent of surgery, and histologic grade of the tumor. The overall average time from detection of tumor to death is about 1 year with surgery alone. Due to the high metastatic potential of mammary carcinoma, adjuvant chemotherapy may improve survival times, but additional studies are needed.

Cadherins are cellular adhesion proteins that play an important role in the formation and maintenance of normal tissue architecture. Placental cadherin (P-cadherin) is a classical cadherin expressed by myoepithelial cells of the mammary gland. Changes in P-cadherin expression in mammary tissue have been implicated in human mammary carcinogenesis. Feline mammary tumors have similar histological and clinical course as human breast cancer; therefore, similar changes in aberrant P-cadherin expression are expected in cats. The present study included histological examination and P-cadherin immunolabelling chemistry of mammary tissue from cats with normal (n=4), hyperplastic (n=12), benign (n=6), and various malignancies (n=39). P-cadherin was aberrantly expressed only in mammary epithelial cells in malignant tumors as similarly observed in human breast cancer. Degree of expression was also positively correlated with histological grade.

Abnormal expression of P-cadherin may provide a promising antibody therapeutic target for humans and cats with mammary neoplasia, in particular in cases with metastatic disease. Disease conditions similar in humans and cats, such as mammary neoplasia, provide an excellent example of the “one world, one health, one medicine” paradigm. [GO]

See also: Hughes K and Dobson JM. Prognostic histopathological and molecular markers in feline mammary neoplasia. Vet J. 2012; 194: 19-26.

Related blog articles:
Treatment of feline mammary cancer with combination therapy (Feb. 2010)
Treatment of feline mammary cancer using surgery and chemotherapy (May 2009)

More on cat health:
Winn Feline Foundation Library
Find us on Facebook
Follow us on Twitter
Join us on Google+

Figueira AC, Teodosio AS, Carvalheira J, Lacerda M, de Matos A and Gartner F. P-cadherin expression in feline mammary tissues. Veterinary Medicine International. 2012; 2012. [Free, full text article}

Feline mammary gland tumors are the third most common neoplasia in the domestic cat after skin and lymphohematopoietic tumors, accounting for 17% of all neoplasms in female cats (but rare in male cats). Mammary epithelial tumors are the most common type of feline mammary tumor, with adenocarcinomas (i.e., tubular, papillary, or solid) predominating. Tumors occur at a mean age between 10 to 12 years with Siamese, domestic short-haired, and tri-colored cats having an increased risk. Unfortunately, most cats have advanced disease when first presented to veterinarians, averaging 5 months after the neoplasia is first noticed. Treatment of choice is radical mastectomy of all glands on the affected side or bilateral mastectomy if possible, because of the high local recurrence rate, high rate of metastasis, and the frequent multicentric origin of feline mammary gland tumors. Often surgery for the opposite side is staged 2-4 weeks later. Also, all regional lymph nodes should be palpated and removed if enlarged. Ovariohysterectomy at an early age (< 6 months old) has a significant sparing effect. Significant factors affecting survival include the size, extent of surgery, and histologic grade of the tumor. The overall average time from detection of tumor to death is about 1 year with surgery alone. Due to the high metastatic potential of mammary carcinoma, adjuvant chemotherapy may improve survival times, but additional studies are needed.

Cadherins are cellular adhesion proteins that play an important role in the formation and maintenance of normal tissue architecture. Placental cadherin (P-cadherin) is a classical cadherin expressed by myoepithelial cells of the mammary gland. Changes in P-cadherin expression in mammary tissue have been implicated in human mammary carcinogenesis. Feline mammary tumors have similar histological and clinical course as human breast cancer; therefore, similar changes in aberrant P-cadherin expression are expected in cats. The present study included histological examination and P-cadherin immunolabelling chemistry of mammary tissue from cats with normal (n=4), hyperplastic (n=12), benign (n=6), and various malignancies (n=39). P-cadherin was aberrantly expressed only in mammary epithelial cells in malignant tumors as similarly observed in human breast cancer. Degree of expression was also positively correlated with histological grade.

Abnormal expression of P-cadherin may provide a promising antibody therapeutic target for humans and cats with mammary neoplasia, in particular in cases with metastatic disease. Disease conditions similar in humans and cats, such as mammary neoplasia, provide an excellent example of the “one world, one health, one medicine” paradigm. [GO]

See also: Hughes K and Dobson JM. Prognostic histopathological and molecular markers in feline mammary neoplasia. Vet J. 2012; 194: 19-26.

Related blog articles:
Treatment of feline mammary cancer with combination therapy (Feb. 2010)
Treatment of feline mammary cancer using surgery and chemotherapy (May 2009)

More on cat health:
Winn Feline Foundation Library
Find us on Facebook
Follow us on Twitter
Join us on Google+

Read More


Thursday, February 18, 2010

Treatment of Feline Mammary Cancer

Borrego JF, Cartagena JC, Engel J. Treatment of feline mammary tumours using chemotherapy, surgery and a COX-2 inhibitor drug (meloxicam): a retrospective study of 23 cases (2002-2007). Veterinary and Comparative Oncology. 2009;7(4):213-221.

Mammary cancer is the third most common cancer in cats. It affects mainly female cats and the mean age at diagnosis is 10-12 years. Unfortunately, 90% of mammary tumors in cats are malignant. These cancers are locally invasive and metastasize to distant locations. Treatment options include radical surgery and various chemotherapy protocols, used either alone or with surgery. However, high quality data on the best treatment approach is lacking. This article evaluates the efficacy of a treatment combination of a COX-2 inhibitor (meloxicam), chemotherapy and surgery in 23 cats with mammary adenocarcinoma. All cats underwent surgery followed by doxorubicin-based chemotherapy. Meloxicam was given long-term, starting the day after surgery. Median survival time was 460 days and the median disease-free interval was 269 days. The survival times are similar to other studies, and do not show an advantage of combining meloxicam with chemotherapy and surgery. Prospective trials with larger numbers of cats are needed to find the optimal treatment for feline mammary cancer. [SL]

Related articles:
McNeill CJ, Sorenmo KU, Shofer FS, et al. Evaluation of adjuvant doxorubicin-based chemotherapy for the treatment of feline mammary carcinoma. Journal of Veterinary Internal Medicine. 2009;23(1):123-129.

Novosad CA, Bergman PJ, O'Brien M G, et al. Retrospective evaluation of adjunctive doxorubicin for the treatment of feline mammary gland adenocarcinoma: 67 cases. J Am Anim Hosp Assoc. March-April 2006;42(2):110-120.

Morre on cat health: Winn Feline Foundation Library
Join us on Facebook
Follow us on Twitter
New for 2010: Subscribe to our e-newsletter
Borrego JF, Cartagena JC, Engel J. Treatment of feline mammary tumours using chemotherapy, surgery and a COX-2 inhibitor drug (meloxicam): a retrospective study of 23 cases (2002-2007). Veterinary and Comparative Oncology. 2009;7(4):213-221.

Mammary cancer is the third most common cancer in cats. It affects mainly female cats and the mean age at diagnosis is 10-12 years. Unfortunately, 90% of mammary tumors in cats are malignant. These cancers are locally invasive and metastasize to distant locations. Treatment options include radical surgery and various chemotherapy protocols, used either alone or with surgery. However, high quality data on the best treatment approach is lacking. This article evaluates the efficacy of a treatment combination of a COX-2 inhibitor (meloxicam), chemotherapy and surgery in 23 cats with mammary adenocarcinoma. All cats underwent surgery followed by doxorubicin-based chemotherapy. Meloxicam was given long-term, starting the day after surgery. Median survival time was 460 days and the median disease-free interval was 269 days. The survival times are similar to other studies, and do not show an advantage of combining meloxicam with chemotherapy and surgery. Prospective trials with larger numbers of cats are needed to find the optimal treatment for feline mammary cancer. [SL]

Related articles:
McNeill CJ, Sorenmo KU, Shofer FS, et al. Evaluation of adjuvant doxorubicin-based chemotherapy for the treatment of feline mammary carcinoma. Journal of Veterinary Internal Medicine. 2009;23(1):123-129.

Novosad CA, Bergman PJ, O'Brien M G, et al. Retrospective evaluation of adjunctive doxorubicin for the treatment of feline mammary gland adenocarcinoma: 67 cases. J Am Anim Hosp Assoc. March-April 2006;42(2):110-120.

Morre on cat health: Winn Feline Foundation Library
Join us on Facebook
Follow us on Twitter
New for 2010: Subscribe to our e-newsletter
Read More


Friday, May 29, 2009

Treatment of Feline Mammary Cancer

McNeill, C. J., K. U. Sorenmo, et al. (2009). "Evaluation of adjuvant doxorubicin-based chemotherapy for the treatment of feline mammary carcinoma." Journal of Veterinary Internal Medicine 23(1): 123-129.

Mammary carcinoma is the third most common cancer of cats. Female cats with a mean age of 10 to 12 years are primarily affected and approximately 90% of mammary tumors are malignant. Mammary tumors are characterized by local invasion into vasculature and surrounding tissues along with metastasis to distant locations such as draining lymph nodes, lungs, and other sites. A retrospective study was performed to evaluate whether adjuvant doxorubicin-based chemotherapy improved outcomes for cats with mammary carcinoma (MC) compared with surgery alone. Seventy-three cats with naturally occurring, biopsy-confirmed MC were included in the study. The surgery alone group contained 37 cats and 36 cats were in the surgery plus chemotherapy group (adjuvant doxorubicin-based chemotherapy). Median disease free survival and overall survival times were compared between groups. This study did not find a benefit to adjuvant doxorubicin-based chemotherapy in cats with MC. Additional studies are recommended to determine whether certain patients with negative prognostic factors (e.g., tumor size at time of surgical intervention) may benefit from adjuvant chemotherapy. [VT]
>> PubMed Abstract

Related Articles:
Overley, B., F. S. Shofer, et al. (2005). "Association between ovarihysterectomy and feline mammary carcinoma." J Vet Intern Med 19(4): 560-3.
>> PubMed Abstract

Viste, J. R., S. L. Myers, et al. (2002). "Feline mammary adenocarcinoma: tumor size as a prognostic indicator." Can Vet J 43(1): 33-7.
>> PubMed Abstract

More on cat health: Winn Feline Foundation Library
Join us on Facebook
McNeill, C. J., K. U. Sorenmo, et al. (2009). "Evaluation of adjuvant doxorubicin-based chemotherapy for the treatment of feline mammary carcinoma." Journal of Veterinary Internal Medicine 23(1): 123-129.

Mammary carcinoma is the third most common cancer of cats. Female cats with a mean age of 10 to 12 years are primarily affected and approximately 90% of mammary tumors are malignant. Mammary tumors are characterized by local invasion into vasculature and surrounding tissues along with metastasis to distant locations such as draining lymph nodes, lungs, and other sites. A retrospective study was performed to evaluate whether adjuvant doxorubicin-based chemotherapy improved outcomes for cats with mammary carcinoma (MC) compared with surgery alone. Seventy-three cats with naturally occurring, biopsy-confirmed MC were included in the study. The surgery alone group contained 37 cats and 36 cats were in the surgery plus chemotherapy group (adjuvant doxorubicin-based chemotherapy). Median disease free survival and overall survival times were compared between groups. This study did not find a benefit to adjuvant doxorubicin-based chemotherapy in cats with MC. Additional studies are recommended to determine whether certain patients with negative prognostic factors (e.g., tumor size at time of surgical intervention) may benefit from adjuvant chemotherapy. [VT]
>> PubMed Abstract

Related Articles:
Overley, B., F. S. Shofer, et al. (2005). "Association between ovarihysterectomy and feline mammary carcinoma." J Vet Intern Med 19(4): 560-3.
>> PubMed Abstract

Viste, J. R., S. L. Myers, et al. (2002). "Feline mammary adenocarcinoma: tumor size as a prognostic indicator." Can Vet J 43(1): 33-7.
>> PubMed Abstract

More on cat health: Winn Feline Foundation Library
Join us on Facebook
Read More